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1. Introduction 
Hepatocellular carcinoma (HCC) is the cancer with the sixth highest incidence in the world.1  
The incidence of this cancer has increased significantly in the United States, Japan and 
several European countries over the last two or three decades. HCC as a cause of death is 
also increasing throughout the world.2-5 Development of new treatments for HCC has 
helped to improve patient prognosis.6, 7  Transcatheter arterial chemoembolization (TACE) is 
one such treatment, and has been applied to patients with multiple or unresectable HCC.8, 9  
However, HCC has been reported to progress within the short period of multiple sessions of 
TACE into a complicated condition, even though the treatment is temporarily effective. In 
recent years, TACE using an emulsion of doxorubicin (ADM) with lipiodol (LPD) (ADM-
LPD emulsion) followed by embolization with gelatin sponge has commonly been 
employed for HCC treatment.10, 11  However, the tumors have been demonstrated to show a 
high frequency of recurrence after TACE.9, 12, 13  Cisplatin (CDDP), a platinum compound, is 
an effective anticancer agent used in the treatment of various malignancies.14  Researchers 
have recently reported that TACE using a suspension of CDDP in LPD may be more 
effective against unresectable HCC than that using ADM-LPD emulsion.15, 16  Moreover, a 
fine-powder formulation of CDDP (DDPH, IA-call; Nipponkayaku, Tokyo, Japan) has also 
been available since 2004 as a therapeutic agent for intra-arterial infusion in Japan. 
In this article, we report the results of a retrospective comparative review of TACE using a 
suspension of DDPH in LPD (DDPH-LPD suspension) and an emulsion of ADM in LPD, in 
terms of the response rate (RR), progression-free survival (PFS) and overall survival (OS). 
Moreover, we analyzed prognostic factors in patients undergoing TACE using DDPH-LPD 
suspension or ADM-LPD emulsion. 
2. Methods 
2.1 Patients 
We reviewed 468 consecutive HCC patients who had undergone TACE using DDPH or 
ADM between April 2004 and September 2008 at the Hospital of Iwate Medical 
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University. HCC was diagnosed based on distinctive findings on ultrasonography (US), 
computed tomography (CT), magnetic resonance imaging (MRI) and angiography, and 
serum levels of des-γ-carboxy prothrombin (DCP) and α-fetoprotein (AFP). Histological 
examination was not always applied. Liver function was evaluated according to the 
Child-Pugh classification.17  Tumor stage was judged by the TNM classification 
established by the International Union Against Cancer.18  The extent of portal vein 
invasion was classified as follows: Vp0, no invasion of the portal vein; Vp1, invasion of 
the third or more distal branch of the left or right portal vein; Vp2, invasion of the second 
branch of the portal vein; Vp3, invasion of the first branch of the portal vein; and Vp4, 
invasion of the trunk of the portal vein. 
We excluded 18 patients with serum bilirubin levels over 3.0 mg/dL, 12 patients with extra-
hepatic metastasis, and 30 patients with uncontrolled ascites. In addition, we excluded 77 
patients who had undergone repeated sessions of TACE using different regimens, and 44 
patients who showed disease progression and received hepatic arterial infusion 
chemotherapy (HAIC) and/or systemic chemotherapy as additional therapy. 
A final total of 287 HCC patients were enrolled in this study. All of the enrolled patients met 
the eligibility criteria for inclusion in the analysis described in the next paragraph. Patients 
were divided into two groups: one group consisting of 120 patients who had undergone 
TACE using DDPH-LPD suspension (DDPH group); and another group consisting of 167 
patients who had undergone TACE using an emulsion of LPD with ADM (ADM group). Of 
the 120 patients in the DDPH group, 44 had also received various additional therapies such 
as radiofrequency ablation (RFA) or surgical operation (OPE) after TACE, and 76 patients 
had undergone TACE alone during the study period. Similarly, 79 patients of the ADM 
group had received various additional therapies such as RFA or OPE after TACE, and 88 
patients had undergone TACE alone without any other therapies during the study period. 
Informed consent was obtained from all patients. The study protocol was approved by the 
Ethics Committee of Iwate Medical University and the study was conducted in accordance 
with the Declaration of Helsinki 1975. 
2.2 Eligibility criteria 
Eligibility criteria for patients in this study were as follows: 1) no evidence of extrahepatic 
metastasis; 2) no evidence of active heart or renal diseases meeting the contraindications for 
ADM and CDDP therapy, respectively; 3) Eastern Cooperative Oncology Group (ECOG) 
performance status (PS)19 level 0-2; 4) no uncontrolled ascites or pleural effusion; and 5) total 
serum bilirubin (T-Bil) less than 3 mg/dL. The presence of underlying liver disease such as 
hepatitis or cirrhosis was confirmed by laboratory, radiological examinations and 
pathological examinations. We classified chronic hepatitis patients into Child-Pugh class A, 
because chronic hepatitis is a known pre-cirrhotic condition. 
2.3 Preparation of the agents for TACE 
We used DDPH or ADM (Adriacin; Kyowa Hakko Kogyo, Tokyo, Japan) mixed with LPD 
(iodized oil; Andre Guerget, Aulnay-sous-Bois, France). 
The DDPH/LPD suspension was prepared by mixing 50 mg of DDPH into 3-10 mL of LPD. 
www.intechopen.com
Transcatheter Arterial Chemo-Embolization with a Fine-Powder  
Formulation of Cisplatin for Unresectable Hepatocellular Carcinoma 
 
251 
The ADM/LPD emulsion was prepared by the following procedure: 10-30 mg of ADM was 
dissolved in 1-2 mL of a contrast medium (Iomeron; Eisai, Tokyo, Japan) and then mixed 
with 3-10 mL of LPD. 
The dosages of LPD and the anticancer drugs were adjusted depending on tumor size, 
number of tumors, degree of liver impairment and renal function, with the maximum dose 
of LPD not allowed to exceed 10 mL. 
2.4 Treatment regimen 
The patient enrolment period for the DDHP and ADM groups extended from May 2006 to 
September 2008 and April 2004 to September 2008, respectively. All patients provided fully 
informed consent prior to TACE. In terms of embolization agents, gelatin sponge particles 
(Gelpart; Nipponkayaku, Tokyo, Japan) were used for all patients. 
After TACE, additional RFA or OPE therapy was provided to patients who met the 
following inclusion criteria: the presence of up to three tumors with none exceeding 30 mm 
in diameter or a solitary tumor less than 50 mm in diameter. Regardless of the additional 
therapy requirement, all patients were followed up with US, CT and/or MRI after 1 month, 
then every 3 months thereafter. TACE was undertaken again when relapse of treated lesions 
and/or new hepatic lesions were detected. These patients received additional TACE using 
the same agent during the follow-up period. TACE or TACE with additional therapy (RFA 
or OPE) was repeated until complete regression of the tumor was obtained, or until the 
patient could no longer be treated. 
2.5 Post-treatment assessment 
Tumor response was assessed by US, CT and/or MRI, conducted 1 month from the start of 
treatment and every 3 months thereafter. We regarded LPD accumulation in the tumor as 
representing a necrotic area, based on previous reports of such LPD retention areas 
corresponding to the necrotic areas on CT.20-23  By measurement of the two largest 
perpendicular diameters of the tumor, we classified tumor response into four categories 
using the following criteria: complete response (CR), complete disappearance or 100% 
necrosis of all tumors; partial response (PR), reduction and/or necrosis, with a decrease of at 
least 50% in all measurable lesions; progressive disease (PD), an increase in tumor size 
exceeding 25% of all measurable lesions or appearance of a new lesion; stable disease (SD), 
disease not qualifying for classification as CR, PR, or PD. 
Toxicity was evaluated using the National Cancer Institute–Common Terminology Criteria 
for Adverse Events, version 3.0 (CTCAE v3.0). 
2.6 Evaluation of therapeutic effects 
We analyzed outcomes in the DDPH and ADM groups in terms of RR, PFS and OS in 
September 2008. In addition, we also evaluated all patients for survival using uni- and 
multivariate analyses. Duration of response was calculated from the date of the start of 
treatment to the date of documented progression. Survival time was calculated from the 
date of the start of treatment to the date of death or last day of follow-up. 
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US, CT and/or MRI were performed as mentioned above. In addition, serum levels of 
biochemical parameters and tumor markers such as AFP and DCP were also measured 
before and after treatment. The same tests were repeated after completion of every session 
of treatment. 
2.7 Statistical analysis 
Differences in background clinical characteristics of patients between the DDPH and ADM 
groups were assessed using the Mann-Whitney U test, logistic regression test, or the 2 test, 
as appropriate. 
PFS and OS were calculated from the date of the start of therapy to the date on which tumor 
progression was documented and the date of patient death, respectively. Both were assessed 
using the Kaplan-Meier life-table method, and differences between the two treatment 
groups were evaluated with the log-rank test. Univariate analysis to identify predictors of 
survival in patients was conducted with the Kaplan-Meier life-table method, and differences 
between groups were evaluated using the log-rank test. Multivariate analysis to identify 
predictors of survival was conducted using the Cox proportional hazards model. Statistical 
significance was defined as a value of P<0.05. All of the above analyses were performed 
using SPSS version 11 software (SPSS, Chicago, IL, USA). 
3. Results 
3.1 Patient profiles (table 1) 
Characteristics of the 287 patients (200 men, 87 women) in both groups are summarized in 
Table 1. Mean age was 68.4 years (range, 21-90 years). 
For the assessment of differences in patient characteristics, patients were divided into two 
groups based on each characteristic, and significant differences were observed between 
the DDPH and ADM groups in relation to the gender distribution, TNM classification, 
tumor size and number of tumors. That is, the DPHH group showed a significantly higher 
proportion of men (P=0.030), higher frequency of more advanced TNM classification 
(P<0.001), and larger tumor size and number (P=0.004, P=0.026, respectively) than the 
ADM group. No significant differences in any of the other characteristics were seen 
between groups. 
In relation to differences in the characteristics of patients with no apparent history of 
additional therapy, significant differences in gender distribution and TNM classification 
were evident between groups, with higher proportions of men (P=0.031) and advanced 
TNM classification (P=0.026) in the DPHH group. No significant differences in any of the 
other characteristics were seen between groups. 
On the other hand, with regard to differences in the characteristics of patients who received 
additional therapy, the DDPH group differed significantly from the ADM group in terms of 
TNM classification, tumor size and number of tumors. That is, TNM classification was more 
advanced (P=0.003), tumor size was larger (P=0.007) and number of tumors was greater 
(P=0.050) in the DDPH group. No significant differences in other patient characteristics were 
evident between groups. 
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 Overall 
Characteristics DDPH ADM P value 
No. of patients 120 167  
Age (years) [Median, (range)] 66 (32-87) 69 (21-90) 0.073 
Gender (Male / Female) 92/28 108/59 0.030 
Etiology (HBV/ HCV / NBNC) 17/83/20 21/119/27 0.911 
Child- Pugh (A / B / C) 76/40/4 103/55/8 0.825 
TNM classification (I-II / III-IV) 29/91 80/87 < 0.001 
Tumor size (≤ 3.0/ >3.0 cm) 44/76 90/77 0.004 
Number of tumors (1-3 / 4) 68/52 116/51 0.026 
PVTT (Vp0-2 / Vp3-4) 106/14 158/9 0.053 
Total bilirubin (≤ 1.5 / >1.5 mg/dL) 106/14 150/16 0.581 
Albumin (≤ 3.5 / >3.5 g/dL) 54/66 73/93 0.863 
AFP (≤ 1000 / >1000 ng/mL) 108/12 155/11 0.301 
DCP (≤ 1000 / >1000 mAU/mL) 99/17 146/17 0.288 
 
 According to additional therapy 
Additional therapy (-) Additional therapy (+) 
 
Characteristics 
DDPH ADM P value DDPH ADM P value 
No. of patients 76 88  44 79  
Age (years) [Median, 
(range)] 
67 
(32-87) 
69 
(21-90) 
0.093 63 
(44-81) 
68 
(42-80) 
0.143 
Gender (Male/Female) 57/19 52/36 0.031 35/9 56/23 0.294 
Etiology 
(HBV/HCV/NBNC) 
11/50/15 8/64/16 0.508 7/32/5 15/53/11 0.818 
Child- Pugh (A/B/C) 47/26/3 45/36/7 0.303 29/14/11 58/19/2 0.598 
TNM classification 
(I-II/III-IV) 
10/66 24/64 0.026 19/25 56/23 0.003 
Tumor size 
(≤ 3.0/>3.0 cm) 
21/55 30/58 0.373 23/21 60/19 0.007 
Number of tumors 
(1-3/4) 
35/41 46/42 0.427 33/11 70/9 0.050 
PVTT (Vp0-2/Vp3-4) 62/14 80/8 0.080 44/0 78/1 0.454 
Total bilirubin 
(≤ 1.5 / >1.5 mg/dL) 
66/10 75/13 0.906 40/4 75/4 0.385 
Albumin 
(≤ 3.5 / >3.5 g/dL) 
38/38 45/42 0.822 16/28 28/51 0.919 
AFP 
(≤ 1000 />1000 ng/mL) 
68/8 79/8 0.776 40/4 76/3 0.225 
DCP(≤ 1000/>1000 
mAU/mL) 
59/14 73/14 0.609 41/3 73/3 0.468 
Table 1. Patient characteristics 
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Data are expressed as median with range values, or the number of patients. HBV, hepatitis B 
virus; HCV, hepatitis C virus; NBNC, negative for hepatitis B surface antigen and HCV 
antibody; PVTT, portal vein tumor thrombosis; AFP, α-fetoprotein; DCP, des-γ-carboxy 
prothrombin. Stages of HCC according to TNM classification were clustered into two 
groups (I–II and III–IV). Tumor characteristics and other parameters were classified as 
follows: tumor size, ≤ 3.0 vs. >3.0 cm; tumor number, 1-3 vs. >4; extent of PVTT, Vp0-2 vs. 
Vp3-4; serum bilirubin, ≤ 1.5 vs. >1.5 mg/dL; serum albumin, ≤ 3.5 vs. >3.5 g/dL; serum 
AFP levels, ≤ 1000 vs. >1000 ng/mL; and serum DCP levels, ≤ 1000 vs. >1000 mAU/mL. 
3.2 Response to therapy (table 2) 
3.2.1 Evaluation of the total subject population 
RR for all 287 patients was evaluated after one session of therapy. Table 2 shows tumor 
responses in the two groups. In the DDPH group, 34 (28.3%), 49 (40.8%), 12 (10.0%) and 25 
(20.9%) patients showed CR, PR, SD and PD, respectively. In the ADM group, 69 (41.4%), 23 
(13.8%), 5 (2.9%) and 70 (41.9%) patients showed CR, PR, SD and PD, respectively. The 
objective response rate (CR + PR / all cases in each group) was thus significantly higher in 
the DDPH group (69.1%) than in the ADM group (55.2%; P=0.0159). 
 
 
 
Overall 
Response DDPH (n=120) ADM (n=167) P value 
CR(%) 34 (28.3%) 69 (41.4%)  
PR(%) 49 (40.8%) 23 (13.8%)  
SD(%) 12 (10.0%) 5 (2.9%)  
PD(%) 25 (20.9%) 70 (41.9%)  
CR+PR(%) 83 (69.1%) 92 (55.2%) 0.016 
 
 
Additional therapy 
(-) (+) 
 
Response 
DDPH 
(n=76) 
ADM (n=88) P value 
DDPH 
(n=44) 
ADM (n=79) P value 
CR(%) 2 (2.7%) 5 (5.7%)  32 (72.7%) 64 (81.0%)  
PR(%) 39 (51.3%) 16 (18.2%)  10 (22.7%) 7 (8.9%)  
SD(%) 23 (30.2%) 5 (5.7%)  2 (4.6%) 0 (0%)  
PD(%) 12 (15.8%) 62 (70.4%)  0 (0%) 8 (10.1%)  
CR+PR(%) 41 (54.0%) 21 (23.9%) <0.001 42 (95.4%) 71 (89.9%) 0.278 
Table 2. Response 
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3.2.2 Evaluation of patients who reported no history of additional therapy 
In the DDPH group, 2 (2.7%), 39 (51.3%), 23 (30.2%) and 12 (15.8%) patients showed CR, PR, 
SD and PD, respectively. In the ADM group, 5 (5.7%), 16 (18.2%), 5 (5.7%) and 62 (70.4%) 
patients showed CR, PR, SD and PD, respectively. The objective response rate was thus 
significantly higher in the DDPH group (54.0%) than in the ADM group (23.9%; P<0.0001). 
3.2.3 Evaluation of patients who reported a history of additional therapy 
In the DDPH group, 32 (72.7%), 10 (22.7%), 2 (4.6%) and 0 (0%) patients showed CR, PR, SD 
and PD, respectively. In the ADM group, 64 (81.0%), 7 (8.9%), 0 (0%) and 8 (10.1%) patients 
showed CR, PR, SD and PD, respectively. No significant difference in objective response rate 
was apparent between groups, with 95.4% in the DDPH group and 89.9% in the ADM group 
(P=0.2778). 
Data are expressed as number of patients and percentages. CR, complete response; PR, 
partial response; SD, stable disease; PD, progressive disease. 
3.3 PFS (fig. 1) 
3.3.1 Evaluation of the entire subject population 
Median PFS in the DDPH group and ADM group was 11.1 months and 5.0 months, 
respectively. PFS rates at 6, 12, 18 and 24 months were 70.0%, 47.0%, 27.2% and 24.5%, 
respectively, in the DDPH group. In contrast, corresponding values were 46.4%, 31.0%, 
21.5% and 18.8%, respectively, in the ADM group. PFS rates were significantly higher in the 
DDPH group than in the ADM group (P=0.0045). 
3.3.2 Evaluation of patients who reported no history of additional therapy 
Median PFS was 7.6 months in the DDPH group and 3.0 months in the ADM group. PFS 
rates at 6, 12, 18 and 24 months were 56.5%, 32.2%, 15.3% and 15.3%, respectively, in the 
DDPH group. In contrast, corresponding values were 18.4%, 10.3%, 5.4% and 5.4%, 
respectively, in the ADM group. PFS rates were significantly higher in the DDPH group 
than in the ADM group (P<0.0001). 
3.3.3 Evaluation of patients who reported a history of additional therapy 
Median PFS was 17.7 months in the DDPH group and 12.9 months in the ADM group. PFS 
rates at 6, 12, 18 and 24 months were 90.7%, 74.9%, 42.1% and 42.1%, respectively, in the 
DDPH group, and 75.9%, 52.6%, 39.3% and 32.3%, respectively, in the ADM group. 
Although no significant differences in PFS rates were apparent between groups, rates 
tended to be higher in the DDPH group than in the ADM group (P=0.1171). 
PFS rate was significantly higher in the DDPH group than in the ADM group in both 
assessment of the entire study population and assessment of patients who reported no 
history of receiving additional therapy (log-rank test: P=0.05, P<0.001, respectively). The 
difference in PFS rates between patients of the two groups who had received additional 
therapy was not significant, but a strong tendency was evident (log-rank test: P=0.117). 
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Fig. 1. Comparison of progression-free survival (PFS) rates between DDPH and ADM groups.  
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3.4 Survival (fig. 2, tables 3, 4) 
3.4.1 Evaluation of the entire subject population 
Median survival time (MST) in the DDPH and ADM groups was ‘not reached’ and 45.3 
months, respectively. OS at 6, 12, 18, and 24 months were 94.7%, 86.3%, 82.3% and 77.5%, 
respectively, in the DDPH group. Corresponding values were 94.3%, 82.7%, 74.9% and 
69.5%, respectively, in the ADM group. No significant differences in OS were seen between 
groups (P=0.236).  
Univariate analysis to identify predictors of survival indicated seven possible factors 
affecting survival: Child-Pugh class; TNM classification; tumor size; number of tumors; 
PVTT; T-Bil; and DCP (Table 3). Multivariate analysis taking all of the factors identified by 
univariate analysis into account identified treatment regimen, Child-Pugh class, number of 
tumors, PVTT and DCP as independent factors affecting survival (Table 4). 
3.4.2 Evaluation of patients who reported no history of additional therapy 
MST in the DDPH and ADM groups was ‘not reached’ and 20.7 months, respectively. OS at 
6, 12, 18, and 24 months were 91.6%, 78.9%, 73.4% and 67.3%, respectively, in the DDPH 
group. Corresponding values in the ADM group were 87.3%, 68.3%, 54.8% and 46.4%, 
respectively. OS was significantly higher in the DDPH group than in the ADM group 
(P=0.046).  
3.4.3 Evaluation of patients who reported a history of additional therapy 
MST in both groups was ‘not reached’. OS at 6, 12, 18 and 24 months were 100%, 100%, 
100% and 100%, respectively, in the DDPH group, compared to 100%, 95.9%, 94.5% and 
90.1%, respectively, in the ADM group. No significant differences in OS were evident 
between groups (P=0.456). 
OS was significantly higher in the DDPH group than in the ADM group in the assessment of 
the entire study population, as well as among patients who reported no history of receiving 
additional therapy (log-rank test: P=0.046). No significant difference in OS was seen 
between patients in the two groups who had received additional therapy (log-rank test: 
P=0.236, P=0.456, respectively). 
HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, negative for hepatitis B surface 
antigen and HCV antibody; PVTT, portal vein tumor thrombosis; AFP, α-fetoprotein; DCP, 
des-γ-carboxy prothrombin. 
3.5 Adverse effects (table 5) 
Table 5 shows a summary of adverse effects in the two groups. Abdominal pain, 
nausea/vomiting, fever, and elevation of serum transaminase levels were observed in most 
patients of both groups, but these symptoms were mild and transient. The frequency of 
nausea/ vomiting was significantly higher in the DDPH group than in the ADM group 
(P<0.0001). In addition, frequencies of occlusion of the hepatic artery and leucopenia were 
significantly higher in the ADM group than in the DDPH group (P<0.001 and P=0.002, 
respectively). No other serious complications or treatment-related deaths were observed in 
either group. 
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Fig. 2. Comparison of OS between DDPH and ADM groups.  
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Variable Hazard ratio 95% confidence interval P value 
Treatment regimen
(ADM vs. DDPH)
0.752 0.425-1.330 0.327 
Age (65 years vs. >65 years) 1.466 0.895-2.400 0.129 
Gender (Female vs. Male) 1.116 0.681-1.828 0.663 
Etiology (NBNC vs. HBV/ HCV) 0.960 0.587-1.572 0.872 
Child Pugh classification
(A vs. B/C) 
1.747 0.105-2.762 0.017 
TNM classification (I-II vs. III-IV) 3.567 2.037-6.244 < 0.001 
Tumor size (≤ 3.0 vs. >3.0 cm) 2.871 1.754-4.701 < 0.001 
Number of tumors (1-3 vs. 4) 4.073 2.550-6.503 < 0.001 
PVTT (Vp0-2 vs. Vp3-4) 6.951 3.804-12.703 < 0.001 
Total bilirubin 
(≤ 1.5 vs. >1.5 mg/dL) 2.512 1.347-4.684 0.004 
Albumin (≤ 3.5 vs. >3.5 g/dL) 0.633 0.400-1.002 0.051 
AFP (≤ 1000 vs. >1000 ng/mL) 1.882 0.860-4.117 0.113 
DCP (≤ 1000 vs. >1000 mAU/mL) 3.266 1.884-5.786 < 0.001 
Table 3. Univariate analysis for identifying predictors of survival 
 
Variable Hazard ratio 
95% confidence 
interval
P value 
Treatment regimen
(ADM vs. DDPH)
0.428 0.196-0.934 0.033 
Child Pugh classification
(A vs. B/C) 
3.102 1.685-5.712 0.001 
Number of tumors (1-3 vs. 4) 5.831 3.041-11.181 <0.001 
PVTT (Vp0-2 vs. Vp3-4) 5.428 2.197-13.409 0.001 
DCP (≤ 1000 vs. >1000 mAU/mL) 3.890 1.747-8.663 0.001 
PVTT, portal vein tumor thrombosis; DCP, des-γ-carboxy prothrombin 
Table 4. Multivariate analysis for identifying predictors of survival  
 
Adverse effect 
Treatment group
P value DDPH group 
(n=120)
ADM group
(n=167)
Nausea / Vomiting 101 (84.2%) 103 (61.6%) <0.001 
Fever 96 (80.0%) 138 (82.6%) 0.571 
Abdominal pain 83 (69.1%) 116 (69.4%) 0.957 
Elevation of trans-aminase levels 87 (72.5%) 121 (72.4%) 0.993 
Liver abscess 1 (0.8%) 2 (1.2%) 0.765 
Hepatic artery occlusion 1 (0.8%) 28 (16.7%) <0.001 
Renal or liver failure 0 (0.0%) 2 (1.2%) 0.229 
Leucopenia 5 (4.2%) 26 (15.6%) 0.002 
Thrombocytopenia 7 (5.8%) 12 (7.2%) 0.650 
Fatigue 38 (31.6%) 51 (30.5%) 0.839 
Table 5. Adverse events 
Data are expressed as number of patients, with percentages indicated in parentheses. 
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4. Discussion 
TACE has been widely used for the treatment of unresectable HCC.8, 9  The most commonly 
used agent in TACE for HCC treatment is an emulsion of LPD and ADM, followed by 
embolization with gelatin sponge particles,10, 11 but tumors frequently recur9, 12, 13 or residual 
tumors are observed at a high rate. CDDP is an effective anticancer agent used in the 
treatment of various malignancies.14  Ono et al.15 reported that TACE using a suspension of 
CDDP powder in LPD was more effective against unresectable HCC than that using an 
emulsion of ADM and LPD. Other investigators have also frequently reported favorable 
results obtained with TACE using a suspension of CDDP powder in LPD in HCC patients.16, 
24 However, the CDDP powder for this therapy was difficult to produce because of the 
characteristics of the drug formulation. CDDP powder thus had to be custom-made in 
individual institutions.25  Consequently, when an institution was able to dispense CDDP 
powder in their own pharmacy department, TACE using a suspension of CDDP powder in 
LPD was undertaken. 
A fine-powder formulation of CDDP, “DDPH”, has been available for intra-arterial infusion 
for HCC treatment since 2004 in Japan. Dispensing of CDDP powder improved with the 
development of DDPH, and DDPH has now come to replace CDDP powder. The DDPH-
LPD suspension for TACE in HCC patients was expected to yield better therapeutic 
outcomes, so TACE using DDPH has become widespread in Japanese institutions. 
Nevertheless, the efficacy of TACE using DDPH-LPD suspension has not yet been reported. 
We therefore compared the outcomes of TACE using DDPH-LPD suspension and an 
emulsion of LPD with ADM. 
The antitumor activity of CDDP is closely associated with the serum concentration of the 
drug.26 Antitumor activity can thus be enhanced by increasing the dose. LPD acts as a 
selective carrier of anticancer agents and as an embolic material;20 the anticancer agent is 
gradually released from the iodized oil. Although the mechanism of topical accumulation of 
LPD in the tumor is not yet precisely understood, this approach is nonetheless used to 
achieve a targeted drug delivery system with long-lasting accumulation in the tumor and 
gradual drug release. Augmented antitumor efficacy and milder side-effects have therefore 
come to be expected with the use of this substance for TACE. In fact, Morimoto et al.27 
investigated the pharmacological advantages of TACE using DDPH for hypervascular 
hepatic tumors in animal experiments. They reported that the tumor concentration of 
platinum agent in the DDPH-LPD-TACE group was about 14-times higher than that in the 
DDPH-hepatic arterial infusion (HAI) group. In addition, they reported that plasma 
concentrations of the platinum agent at 5 and 10 min from start of infusion were lower in the 
DDPH-LPD-TACE group than in the DDPH-HAI group. Based on those findings, we 
decided to perform TACE using DDPH-LPD suspension. 
Analysis of the results for the entire study population revealed that the objective response 
rate was significantly higher in the DDPH group than in the ADM group. Moreover, while 
no significant difference in OS was seen between groups, the OS of patients who had not 
received any additional therapy in the DDPH group was significantly higher than that of 
patients with no history of additional therapy in the ADM group. This could be explained as 
being due to the fact that TACE with ADM cannot be repeated as required, given the high 
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frequency of adverse effects of ADM such as leucopenia, severe vascular changes and 
occlusion of the hepatic artery.15, 28, 29  In fact, the incidences of leucopenia and occlusion of 
the hepatic artery were significantly higher in the ADM group in our study than in the 
DDPH group. Second, we concluded that anthracyclines such as ADM may be relatively less 
effective against HCC; this is attributable to high expression levels of P-glycoprotein, which 
transports antitumor agents such as anthracyclines and vinca alkaloids from cells with a 
highly active efflux mechanism in HCC tumors.30 
On the other hand, Pelletier et al.31 reported that TACE with CDDP sometimes caused 
severe complications, such as acute hepatic failure, without providing any significant 
improvement in survival rate. Severe complications could be expected with the high doses 
of CDDP used in that study. Modification of the CDDP dose used for the treatment to 50 mg 
of DDHP in our study resulted in lower severity of complications. 
In terms of our results, no significant differences in objective response rate or OS were 
identified between DDPH and ADM groups in patients who reported a history of previous 
additional therapy. However, considering that the observation period for the DDPH group 
was shorter than that for the ADM group and that PFS tended to be longer in the DDPH 
group as compared with that in the ADM group, a significant difference in OS may be 
observed if the DDPH group was followed up for a longer period. 
To avoid the confounding effects of any deviations in patient characteristics causing an 
impact on the results, such as the gender distribution, TNM classification, or larger size or 
number of tumors, we used multivariate analysis to compare efficacy between regimens. 
This analysis identified the treatment regimen employed for TACE as one of the most 
important prognostic factors. 
5. Conclusion 
We conclude that TACE using DDPH-LPD suspension could provide a useful treatment 
strategy for HCC patients, although further studies are required for a more thorough 
evaluation of the effectiveness of this therapy. 
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